paclitaxel,eribulin,trastuzumab deruxtecan,capecitabine,nab-paclitaxel,gemcitabine
daiichi sankyo,astrazeneca
['biomarker', 'mbc', 'db04', 't-dxd', 'bcsm']
her2-low mbc poster discussion by of t-dxd assoc with improved pfs over tpc in all biomarker groups (db04) her2 expression changes over time and between sites adc sequencing - small study suggests changing target can be effective #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.